New hope for advanced colon cancer patients in Second-Line treatment trial

This study is testing whether a drug called regorafenib works better than standard second-line treatments for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). The trial will enroll 60 patients whose cancer progressed after initial treatment but who still have relatively favorable health. Researchers will compare how long patients live without their cancer getting worse, their overall survival, and their quality of life between the two treatment groups.